

You asked:

1. In the last 6 months, how many patients with Hereditary angioedema (HAE) have been treated with:

- **Berint**
- **Cinryze**
- **Firazyr**
- **Ruconest**
- **Takhzyro**
- **Tranexamic acid**
- **Other**

The Health Board does not hold this information. Patients with Hereditary angioedema (HAE) are seen in the immunology service at the University Hospital in Wales. Therefore, you may wish to transfer this element of your request to Cardiff and Vale University Health Board via the following email address: CAV_FOI.Requests@wales.nhs.uk

2. Over the past 6 months, how many patients with persistent / chronic* Immune thrombocytopenia purpura [ITP] have you treated [include all treatments such as steroids, splenectomy, immune globulins, Rituximab and TPOs]?

***Patient has ITP for over 6 months and does not respond to standard active treatments**

I can confirm that the Health Board does not centrally record this level of detail. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

3. Over the past 6 months, how many ITP patients have you treated with;

- **Eltrombopag [Revolade]** - Less than 5 patients
- **Romiplostim [Nplate]** – Less than 5 patients

Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

4. Over the past 6 months, how many patients with persistent / chronic* Immune thrombocytopenia purpura [ITP] were new to treatment with the following;

- **Eltrombopag [Revolade]**
- **Romiplostim [Nplate]**

***Patient has ITP for over 6 months and does not respond to standard active treatments**

None.